Work

A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps7080

Authors: Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Michael DeFilipp, Mary-Jane Lombardo, Christopher B. Ford, Jonathan U. Peled, Marcel R. M. Van Den Brink, Lisa von Moltke, Bindu Tejura

Institutions: Memorial Sloan Kettering Cancer Center, University of Chicago, Mayo Clinic Hospital, Massachusetts General Hospital, Seres Therapeutics (United States)

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Seres Therapeutics

OpenAlex ID: W4379283358

Cites:

Cited by: 1

Related to: 10